Klin Farmakol Farm. 2023;37(3):108-111 | DOI: 10.36290/far.2023.019

Treatment of gout, traditional and new pharmacotherapy use

Ján Kamenický, Monika Laššánová
Ústav farmakológie a klinickej farmakológie LF UK, Bratislava

Gout (arthritis urica) is chronic metabolic multifactor disease as a result of the hyperuricaemia. The disease is purine metabolism disorder. It belongs to treatable rheumatic diseases. Its origin is based on genetic or external factors. Gout's pathological manifestations are acute and chronic gouty arthritis, tophi formation, kidney impairment and urolithiasis. The asymptomatic hyperuricaemia period comes before acute gouty attack. Hyperuricaemia is the most crucial laboratory finding. In treatment management of gout there are used nonpharmacological measures and pharmacotherapy. To nonpharmacological measures there belong low purine diet and lifestyle modifications. Pharmacotherapy of gout is as follows: anti-inflammatory drugs (non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, monoclonal antibodies, glucocorticoids) and hyperuricaemia decreasing drugs (uricostatics, uricosuric agents, uricases). Uricosuric agents are not being presently used in the Slovak Republic just as in the Czech Republic, pegloticase is not being registered in the European Union at the moment. Colchicine and NSAIDs are first choice medicine for inflammation and pain reduction and allopurinol for hyperuricaemia reduction. Febuxostat is second choice medicine for hyperuricaemia reduction. Monoclonal antibodies and uricases as a new treatment management are second choice medicine. Second choice medicine is recommended for the patients with traditional pharmacotherapy intolerance or suffering from severe polyarticular gout.

Keywords: gout, hyperuricaemia, arthritis urica, treatment of gout, pharmacotherapy of gout.

Accepted: October 12, 2023; Published: October 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kamenický J, Laššánová M. Treatment of gout, traditional and new pharmacotherapy use. Klin Farmakol Farm. 2023;37(3):108-111. doi: 10.36290/far.2023.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pavelka K, Vencovský J, Horák P, et al. Revmatologie. Praha: Maxdorf; 2018.
    2. Bošmanský K. Reumatické choroby a ich vplyv na pohybové ústrojenstvo. Bratislava: Ústav zdravotnej výchovy; 1997.
    3. Rovenský J, et al. Klinická reumatológia. Martin: Osveta; 2000.
    4. Ďurišová E. Dna: manažment a novšie terapeutické možnosti. Zdravotnícke noviny. Lekárske listy. 2021;70(4):12-15.
    5. Mohan H. Patológia. Bratislava: Balneotherma; 2015.
    6. Ďuriš I, Hulín I, Bernadič M. Princípy internej medicíny. Bratislava: SAP; 2001.
    7. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis [Internet]. 2017;76:29-42. [cited 2023 Aug 29]. Available from: https://ard.bmj.com/content/76/1/29.long. Go to original source... Go to PubMed...
    8. Líška D. Nefarmakologická liečba dny. Vnitř Lék [Internet]. 2021;67(e2):e25-e28 [cited 2021 Nov 11]. Available from: https://casopisvnitrnilekarstvi.cz/pdfs/vnl/2021/02/14.pdf. Go to original source...
    9. Lamb KL, Lynn A, Russell J, et al. Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial. BMJ [Internet]. 2020;10:e035108 [cited 2022 Jan 04]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073821/. Go to original source... Go to PubMed...
    10. Mirossay L, Mojžiš J. Základná farmakológia a farmakoterapia. Košice: Equilibra; 2021.
    11. Švihovec J, Bultas J, Anzenbacher P, et al. Farmakologie. Praha: Grada; 2020.
    12. Krystexxa Withdrawal of the marketing authorisation in the European Union [Internet]. [cited 2022 Jul 15]. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-krystexxa-withdrawal-marketing-authorisation-european-union_en.pdf.
    13. Súhrn charakteristických vlastností lieku Alopurinol Sandoz 100 mg Alopurinol Sandoz 300 mg tablety [Internet]. [cited 2020 Aug 01]. Available from: https://www.sukl.sk/hlavna-stranka/slovenska-verzia/pomocne-stranky/detail-lieku?page_id=386&lie_id=9727B.
    14. Mirossay L, et al. Základná farmakológia a farmakoterapia. Košice: Equilibria; 2009.
    15. Súhrn charakteristických vlastností lieku Colchicum-Dispert 0,5 mg obalené tablety [Internet]. [cited 2020 Aug 01]. Available from: https://www.sukl.sk/hlavna-stranka/slovenska-verzia/pomocne-stranky/detail-lieku?page_id=386&lie_id=26600.
    16. Súhrn charakteristických vlastností lieku ADENURIC 80 mg filmom obalené tablety [Internet]. [cited 2021 Dec 09]. Available from: https://www.ema.europa.eu/en/documents/product-information/adenuric-epar-product-information_sk.pdf.
    17. Rovenský J, et al. Gerontorevmatologie. Praha: Galén; 2014.
    18. Tesař V, et al. Biologická a cílená léčba. Praha: Mladá fronta; 2018.
    19. Súhrn charakteristických vlastností lieku Ilaris 150 mg prášok na injekčný roztok [Internet]. [cited 2022 Mar 04]. Available from: https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_sk.pdf.
    20. EPAR summary for the public Krystexxa pegloticase [Internet]. [cited 2022 Jul 15]. Available from: https://www.ema.europa.eu/en/documents/overview/krystexxa-epar-summary-public_en.pdf.
    21. Pavelka K. Nové pohledy na léčbu hyperurikémie a dny. Interní Med [Internet]. 2008;10(6):268-272. [cited 2021 Dec 07]. Available from: https://www.internimedicina.cz/pdfs/int/2008/06/02.pdf.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.